Clinical trials: Overweight and Obesity
Obesity
A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with…
- Trial name
- AMPLIFY-1 (NCT07881432)
- Testing
- eloralintide and tirzepatide, Eloralintide, Tirzepatide
- Where
- 155 sites in United States, Argentina and 7 more
- Volunteers
- 2,115 people
- Sponsor
- Eli Lilly and Company
Healthy Participants
A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants
The purpose of this study is to evaluate the safety, tolerability, and drug level of Pegbelfermin in healthy overweight and obese Chinese and Korean participants.
- Trial name
- NCT04649710
- Testing
- BMS-986036
- Where
- 2 sites in China, South Korea
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Overweight or Obesity
Study Exploring the Supportive Effect of Acarbose in Weight Management
This is a randomized, double-blind study in participants with overweight or obesity in which the effect of acarbose and the impact of dose on efficacy, safety and tolerability is investigated by comparing the EMP16 combination…
- Trial name
- NCT05934110
- Testing
- EMP16-120/40, MR orlistat 120 mg, Conventional orlistat 120 mg,
- Where
- 3 sites in Sweden
- Volunteers
- 320 people
- Sponsor
- Empros Pharma AB
Obesity/Overweight
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study in adult obese/overweight subjects in China to evaluate the efficacy and safety of GZR18 Injection in the subjects.
- Trial name
- NCT06728124
- Testing
- GZR18
- Where
- China
- Volunteers
- 630 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Obesity
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112
1. Study Objective: The objective of this phase 1 clinical trial is to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and food effect of HSG4112 after oral administration in healthy male…
- Trial name
- NCT04732988
- Testing
- HSG4112
- Where
- 2 sites in South Korea
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Glaceum
Health Adult Subjects, Obesity & Overweight
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
Randomized, Placebo-controlled Study to determine the safety and tolerability of multiple oral doses of TIX100 administered daily for 28 days to otherwise healthy overweight/obese subjects.
- Trial name
- NCT07675590
- Testing
- TIX100
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- TIXiMED, Inc.
Overweight, Obesity
DBRPC Study to Evaluate the Efficacy and Safety of IQP-AE-103 in Overweight and Moderately Obese Subjects
The main study objective is to evaluate the efficacy of IQP-AE-103 in reducing body weight in overweight and moderately obese subjects, in the context of an energy restricted diet.
- Trial name
- NCT04086797
- Testing
- IQP-AE-103
- Where
- Germany
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Perrigo CSCI
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2…
- Trial name
- NCT06972459
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 800 people
- Sponsor
- Eli Lilly and Company
Obesity
A Multicenter Study for Pre-Surgical Weight Loss
The purpose of the study is to evaluate the safety and initial efficacy of the EndoBarrier device compared to a diet control in patients who require weight loss prior to their Bariatric surgery.
- Trial name
- NCT00830440
- Testing
- EndoBarrier Device, Diet & Lifestyle Counseling
- Where
- Netherlands
- Volunteers
- 43 people
- Sponsor
- Morphic Medical Inc.
NAFLD, NASH
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT06410924
- Testing
- DD01
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neuraly, Inc.
Obesity
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone.
- Trial name
- NCT06373146
- Testing
- Tirzepatide, Mibavademab
- Where
- 17 sites in United States
- Volunteers
- 392 people
- Sponsor
- Eli Lilly and Company
Obstructive Sleep Apnea (OSA) and Obesity
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy
This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy and safety of the HDM1005 in patients with obstructive sleep apnea (OSA) and obesity receiving positive airway pressure (PAP)…
- Trial name
- NCT07794397
- Testing
- HDM1005
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity & Overweight, Gut
Precision Nutrition Recommendations Generated by Metataxonomic Microbiome Testing Improve Food Group Choices and Intestinal Health Indicators in an Obese Population in Colombia
This study evaluated whether personalized dietary recommendations based on gut microbiome testing can improve intestinal health and food choices in adults with obesity in the region of Antioquia, Colombia.
- Conditions
- Obesity & Overweight, Gut, Microbiome
- Trial name
- NCT07492485
- Testing
- Personalized dietary recommendations
- Where
- Colombia
- Volunteers
- 50 people
- Sponsor
- Astrolab bio
Obesity
High Density Lipoprotein Turnover
The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period.
- Trial name
- NCT00408148
- Testing
- Rimonabant
- Where
- 4 sites in Australia, Finland and 2 more
- Volunteers
- 64 people
- Sponsor
- Sanofi
Atherosclerotic Cardiovascular Disease, Overweight
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
- Conditions
- Atherosclerotic Cardiovascular Disease, Overweight, Obesity
- Trial name
- MARITIME-CV (NCT07037433)
- Testing
- Maridebart Cafraglutide
- Where
- 783 sites in United States, Argentina and 34 more
- Volunteers
- 12,800 people
- Sponsor
- Amgen
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- Lenbelintide
- Where
- 220 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF)
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
This is a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in Chinese subjects with heart failure with ejection fraction retention/mild ejection fraction…
- Conditions
- Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction
- Trial name
- NCT06862908
- Testing
- IBI362
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Overweight and Obese Volunteers
Evaluate LAE102 in Healthy and Overweight/Obese Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose…
- Trial name
- NCT06493084
- Testing
- LAE102 intravenous administration, LAE102 subcutaneous administration, LAE102 multiple subcutaneous administration
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Laekna Limited
Gastroenterology
Efficacy Evaluation of Dai Dai Flower on Body Weight
To assess the Dai Dai flower extract on body weight control
- Trial name
- NCT04692792
- Testing
- Dai Dai flower drink
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Obesity, Overweight
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a…
- Trial name
- NCT06603571
- Testing
- LY3841136, Tirzepatide
- Where
- 52 sites in United States, Argentina
- Volunteers
- 367 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.